Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows From Operating Activities:
Net loss	$ (21,163,460)	$ (17,383,940)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,499,087	1,590,171
Amortization of debt discount	247,604	46,790
Unrealized (gain)/loss on investments in equity securities	(437,762)	87,850
Realized loss on investments in equity securities	804,772	0
Realized gain on available-for-sale investments	(9,952)	(62,484)
Stock-based compensation expense	6,354,546	5,351,265
Accelerated stock-based compensation expense	0	10,789,774
Loss on disposal of property and equipment	213,892	158,872
Provision for bad debt	63,979	42,085
Changes in operating assets and liabilities:
Accounts receivable	(749,290)	(3,995,609)
Inventories	(2,661)	(130,406)
Prepaid expenses and other current assets	151,519	(203,736)
Deposits	(98,451)	(55,849)
Change in operating lease right-of-use assets and lease liabilities	61,062	(9,538)
Accounts payable and other accrued expenses	6,365,123	1,268,267
Accrued compensation and related expenses	651,033	304,676
Deferred revenue	(130,892)	136,931
Deferred tax liability	27,008	0
Net cash used in operating activities	(5,152,843)	(2,064,881)
Cash Flows From Investing Activities:
Purchases of property and equipment	(5,118,803)	(4,188,943)
Purchases of short-term investments	(136,293,195)	(43,044,925)
Sales/maturities of short-term investments	142,276,244	3,995,000
Cash paid for acquisition	0	(20,429,651)
Patent and trademark costs	(116,296)	(48,470)
Net cash provided by (used in) investing activities	747,950	(63,716,989)
Cash Flows From Financing Activities:
proceeds from public offering, net of offering costs	0	68,810,718
Proceeds from exercise of stock options and warrants	8,311,895	4,283,895
Proceeds from issuance of convertible senior notes	115,000,000	0
Payment of deferred financing costs	(4,118,495)	(19,748)
Repayment of finance lease liabilities	(51,711)	(17,261)
Net cash provided by financing activities	119,141,689	73,057,604
Effect of exchange rates on cash and cash equivalents	15,517	(17,705)
Net change in cash and cash equivalents	114,752,313	7,258,029
Cash and cash equivalents - beginning of period	47,234,770	37,327,125
Cash and cash equivalents - end of period	161,987,083	44,585,154
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Net unrealized gain/(loss) on available-for-sale securities	250,643	(16,382)
Reclassification of realized gain on available-for-sale debt securities to earnings	18,800	21,809
Financing costs included in accounts payable and accrued liabilities	472,867	0
Fixed assets included in accounts payable and accrued liabilities	326,846	158,239
Purchase of equipment through finance lease obligations	$ 204,516	$ 0